UK markets close in 1 hour 45 minutes
  • FTSE 100

    7,333.92
    +10.51 (+0.14%)
     
  • FTSE 250

    19,054.27
    -297.00 (-1.53%)
     
  • AIM

    896.47
    -11.14 (-1.23%)
     
  • GBP/EUR

    1.1560
    -0.0015 (-0.13%)
     
  • GBP/USD

    1.2119
    -0.0065 (-0.53%)
     
  • BTC-GBP

    16,484.06
    -973.63 (-5.58%)
     
  • CMC Crypto 200

    432.40
    -7.26 (-1.65%)
     
  • S&P 500

    3,803.04
    -18.51 (-0.48%)
     
  • DOW

    30,951.54
    +4.55 (+0.01%)
     
  • CRUDE OIL

    113.07
    +1.31 (+1.17%)
     
  • GOLD FUTURES

    1,830.50
    +9.30 (+0.51%)
     
  • NIKKEI 225

    26,804.60
    -244.87 (-0.91%)
     
  • HANG SENG

    21,996.89
    -422.08 (-1.88%)
     
  • DAX

    13,059.67
    -172.15 (-1.30%)
     
  • CAC 40

    6,042.27
    -43.75 (-0.72%)
     

Protein Kinase Inhibitors in Oncology Analysis Service 2022: Must have Handbook for Any Business Developer, BI/CI Operative or Clinical Developer

·4-min read
Company Logo
Company Logo

Dublin, June 15, 2022 (GLOBE NEWSWIRE) -- The "Protein Kinase Inhibitors in Oncology: Analytical Tool" report has been added to ResearchAndMarkets.com's offering.

Protein Kinase Inhibitors in Oncology: Analytical Tool is the must have handbook for any business developer, BI/CI operative or clinical developer who needs to be on top of this hot and fast moving area of oncology.

Your Protein Kinase Inhibitors in Oncology: Analytical Tool covers more than 508 companies plus partners who are today developing 1668 PKI drugs where of 940 are in active development in cancer across 322 different targets. Any data and/or analysis from the Analytical Tool is yours to keep and data/graphs/tables can be easily exported into Excel/PDF and various graphic formats for mixing with your own proprietary information.

This unique product is truly the only tool of its kind and is designed to give you a competitive edge in your PKI drug surveillance and intelligence, allowing you to power your decision making and advance your own interests.

Kinase-targeted cancer therapies became really big with imatinib (Gleevec), a landmark drug that has vastly improved the outcomes of patients with chronic myelogenous leukemia. With the human genome encoding 538 protein kinases and many of these kinases being associated with human cancer initiation and progression, this field carries a lot of promise for more treatment successes in the future.

Keeping you "In the know"

Simply put, our mission is to fuel your knowledge of oncology, to make you the first to know about very early technologies and startups, emerging clinical trial results, drug approvals and the ever-changing competitive landscape.

Let our expertise work for you

With a simple point and click interface you can navigate the environment of current development, drill down into specific areas such as ongoing combination trials, biomarker analysis, selected scientific abstracts etc. and generate drug profiles, drug target profiles and company profiles (including Business Development & Licensing contacts). Any analysis generated by you is packed with presentation-ready graphs and tables to use in your reports and presentations.

Your key to access development at the world-leading cancer meetings

The Protein Kinase Inhibitors in Oncology: Analytical Tool is continuously updated according to twelve of the world's most influential meetings in oncology (AACR, ASCO, ASGCT, ASH, CMIT, EHA, EORTC-NCI-AACR, ESMO, SITC and BIO (International, Europe and Asia). If you are not able to attend any of the conference(s) in person, this Analytical Tool ensures that you are not missing out on the important take home messages you need to know about.

Run combination therapy analysis like no other

The Protein Kinase Inhibitors in Oncology: Analytical Tool delivers comprehensive combination therapy analysis, allowing you to analyze combination therapies from multiple perspectives; from a single drug to virtually any cross section of oncology drugs of interest.

Unparalleled biomarker surveillance

We also provide an outstanding oncology clinical biomarker surveillance & analysis, highlighting clinical phenotyping and patient stratification in trials. This analysis is based on our monitoring of the presence and usage of more than 1,000 biomarkers across tens of thousands of cancer clinical trials.

Support and inspiration at your finger-tips

You also have access to a great selection of How-to Training Videos showing best practice approaches to aspects such as competitive pipeline analysis right through to many real world case examples put forward by other users of our Analytical Tools.

A tool to grow with and keep you informed

Unlike a static report which just represents a particular snapshot in time, all of the Analytical Tools come with one year of online access to twice-weekly updates in both contents and features, pipeline alerts and online support etc. You can choose to renew your access to these updates and support on a yearly basis or go over to our industry leading full service platform covering all oncology drug development, 1stOncology.

Protein Kinase Inhibitors in Oncology: Analytical Tool achieves this by continuously scanning development in PKI and reporting:

  • Deals & Collaborations

  • New technologies/drugs (emerging from patents, grants, abstracts (see Conference Coverage) etc.)

  • Funding/Grants/IPOs

  • Filings & Approvals

  • Latest Clinical Trial Development & Results

  • Newly launched clinical trials

  • Conference Coverage of the world's twelve leading meetings in oncology*

  • Quarterly & Annual Reporting

Identify, prioritize, and lead scientific assessment of oncology opportunities and competition by multiple factors such as:

  • Emerging Technologies

  • Target Novelty

  • Recent Funding

  • Early & Late Stage Pipeline

  • Biomarker/Companion Diagnostic Development (featured below)

  • Entered Deals & Alliances

  • Conference surveillance of world leading cancer meetings (featured below)

  • Combination Therapy Choices (featured below)

  • Outcome of Clinical Trials

  • Indication Selection & Expansion Choices

  • Drug Repositioning Opportunities

For more information about this report visit https://www.researchandmarkets.com/r/d0vc0s

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting